MedTrace Logo

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

NCT01163487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-06-16

No results posted yet for this study

Summary

The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor hypoxia.

Conditions

Interventions

DRUG

Dichloroacetate

25-50mg/kg per day; oral

DEVICE

EF5

21 mg/kg; IV

Sponsors & Collaborators

  • Daniel T. Chang

    lead OTHER

Principal Investigators

  • Daniel T Chang · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2015-02-28
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163487 on ClinicalTrials.gov